|Mr. Stephen F. Ghiglieri||Interim Chief Exec. Officer, Chief Financial Officer and Principal Accounting Officer||188.32k||N/A||55|
|Mr. Thomas J. Knapp J.D.||Interim Gen. Counsel and Corp. Sec.||427.69k||N/A||64|
|Dr. Bijan Nejadnik M.D.||Chief Medical Officer and Exec. VP||542.56k||N/A||55|
|Mr. John Thomas Burns CPA||VP of Fin. and Corp. Controller||235.6k||N/A||32|
|Ms. Remy Bernarda MBA, IRC||Sr. VP of Investor Relations & Corp. Communications||N/A||N/A||N/A|
Galena Biopharma, Inc., a biopharmaceutical company, develops hematology and oncology therapeutics that address unmet medical needs. The company develops GALE-401 (anagrelide controlled release), which completed Phase II clinical trial for the treatment of patients with myeloproliferative neoplasms to lower elevated platelet levels. It also develops NeuVax (nelipepimut-S), which is in Phase IIb clinical trial in combination with trastuzumab for HER2 1+ and 2+ node positive and high-risk node negative breast cancer patients; Phase II clinical trial in combination with trastuzumab for HER2 3+ breast cancer patients; Phase II clinical trial for women with ductal carcinoma in situ of the breast; and Phase II clinical trial for patients with gastric cancer. In addition, the company develops GALE-301 and GALE-302 for ovarian, endometrial, and breast cancers. It has strategic development and commercialization partnership with Dr. Reddys Laboratories Ltd. for NeuVax in breast and gastric cancers. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Galena Biopharma, Inc. in September 2011. Galena Biopharma, Inc. was founded in 2003 and is based in San Ramon, California.
Galena Biopharma, Inc.’s ISS Governance QualityScore as of May 1, 2017 is 9. The pillar scores are Audit: 5; Board: 8; Shareholder Rights: 9; Compensation: 8.